Jessica M. Rosenholm

Prof. Dr. Jessica M. Rosenholm

Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
VMVijay Mishra
Vijay Mishra
Kuldeep BansalKuldeep Bansal
Kuldeep Bansal
AVAsit Verma
Asit Verma
NYNishika Yadav
Nishika Yadav
STSourav Thakur
Sourav Thakur
Jessica M. RosenholmJessica M. Rosenholm
Jessica M. Rosenholm
Solid lipid nanoparticles (SLNs) are nanocarriers developed as substitute colloidal drug delivery systems parallel to liposomes, lipid emulsions, polymeric nanoparticles, and so forth. Owing to their unique size dependent properties and ability to incorporate drugs, SLNs present an opportunity to build up new therapeutic prototypes for drug delivery and targeting. SLNs hold great potential for attaining the goal of targeted and controlled drug delivery, which currently draws the interest of researchers worldwide. The present review sheds light on different aspects of SLNs including fabrication and characterization techniques, formulation variables, routes of administration, surface modifications, toxicity, and biomedical applications.

23 August 2010 in Nanoscale
Verified
Journal Article
Closed access
PDF file
Jessica M. RosenholmJessica M. Rosenholm
Jessica M. Rosenholm
CSCecilia M. Sahlgren
Cecilia M. Sahlgren
MLMika Lindén
Mika Lindén
One of the big challenges of medicine today is to deliver drugs specifically to defected cells. Nanoparticulate drug carriers have the potential to answer to this call, as nanoparticles can cross physiological barriers and access different tissues, and also be provided in a targetable form aimed at enhancing cell specificity of the carrier. Recent developments within material science and strong collaborative efforts crossing disciplinary borders have highlighted the potential of mesoporous silica nanoparticles (MSNs) for such targeted drug delivery. Here we outline recent advances which in this sense push MSNs to the forefront of drug delivery development. Relatively straightforward inside-out tuning of the vehicles, high flexibility, and potential for sophisticated release mechanisms make these nanostructures promising candidates for targeted drug delivery such as ‘smart’ cancer therapies. Moreover, due to the large surface area and the controllable surface functionality of MSNs, they can be controllably loaded with large amounts of drugs and coupled to homing molecules to facilitate active targeting, simultaneously carrying traceable (fluorescent or magnetically active) modalities, also making them highly interesting as theragnostic agents. However, the increased relative surface area and small size, and flexible surface functionalization which is beneficially exploited in nanomedicine, consequently also includes potential risks in their interactions with biological systems. Therefore, we also discuss some safety issues regarding MSNs and highlight how different features of the drug delivery platform influence their behaviour in a biological setting. Addressing these burning questions will facilitate the application of MSNs in nanomedicine.

22 September 2004 in Chemistry of Materials
Verified
Journal Article
Closed access
JAJenny Andersson
Jenny Andersson
Jessica M. RosenholmJessica M. Rosenholm
Jessica M. Rosenholm
SASami Areva
Sami Areva
MLMika Lindén
Mika Lindén

23 December 2008 in ACS Nano
Verified
Journal Article
Closed access
Jessica M. RosenholmJessica M. Rosenholm
Jessica M. Rosenholm
AMAnnika Meinander
Annika Meinander
EPEmilia Peuhu
Emilia Peuhu
RNRasmus Niemi
Rasmus Niemi
JEJohn E. Eriksson
John E. Eriksson
MLMika Lindén
Mika Lindén

1 September 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
Aziz MalekiAziz Maleki
Aziz Maleki
HKHelene Kettiger
Helene Kettiger
ASAurélie Schoubben
Aurélie Schoubben
Jessica M. RosenholmJessica M. Rosenholm
Jessica M. Rosenholm
Valeria AmbrogiValeria Ambrogi
Valeria Ambrogi
MHMehrdad Hamidi
Mehrdad Hamidi

27 April 2023 in Life
Verified
Journal Article
Open access
PDF file
LKLakshmi Kumari
Lakshmi Kumari
YCYash Choudhari
Yash Choudhari
PPPreeti Patel
Preeti Patel
GGGhanshyam Das Gupta
Ghanshyam Das Gupta
DCDilpreet singh chahal
Dilpreet singh chahal
BKBalak Das Kurmi
Balak Das Kurmi
A drug’s aqueous solubility is defined as the ability to dissolve in a particular solvent, and it is currently a major hurdle in bringing new drug molecules to the market. According to some estimates, up to 40% of commercialized products and 70–90% of drug candidates in the development stage are poorly soluble, which results in low bioavailability, diminished therapeutic effects, and dosage escalation. Because of this, solubility must be taken into consideration when developing and fabricating pharmaceutical products. To date, a number of approaches have been investigated to address the problem of poor solubility. This review article attempts to summarize several conventional methods utilized to increase the solubility of poorly soluble drugs. These methods include the principles of physical and chemical approaches such as particle size reduction, solid dispersion, supercritical fluid technology, cryogenic technology, inclusion complex formation techniques, and floating granules. It includes structural modification (i.e., prodrug, salt formation, co-crystallization, use of co-solvents, hydrotrophy, polymorphs, amorphous solid dispersions, and pH variation). Various nanotechnological approaches such as liposomes, nanoparticles, dendrimers, micelles, metal organic frameworks, nanogels, nanoemulsions, nanosuspension, carbon nanotubes, and so forth have also been widely investigated for solubility enhancement. All these approaches have brought forward the enhancement of the bioavailability of orally administered drugs by improving the solubility of poorly water-soluble drugs. However, the solubility issues have not been completely resolved, owing to several challenges associated with current approaches, such as reproducibility in large scale production. Considering that there is no universal approach for solving solubility issues, more research is needed to simplify the existing technologies, which could increase the number of commercially available products employing these techniques.